Premium
Necrotizing fasciitis in two patients with myelodysplastic syndrome treated with azacitidine
Author(s) -
Lai ShiueWei,
Huang TzuChuan,
Ye RenHua,
Wu YiYing
Publication year - 2015
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12365
Subject(s) - azacitidine , medicine , fasciitis , myelodysplastic syndromes , dermatology , urinary system , broad spectrum , surgery , bone marrow , biochemistry , gene expression , chemistry , dna methylation , combinatorial chemistry , gene
Azacitidine is a novel agent for treating myelodysplastic syndromes (MDS). It has a relatively safe toxicity profile with very few reported skin toxicities. Patients with MDS were prone to get severe infections, especially via respiratory tract, urinary system, and bloodstream. However, necrotizing fasciitis (NF) is a relatively rare event in patients with MDS, and it is hard to diagnose early. Here, we report two MDS cases that developed NF in lower extremities while receiving azacitidine treatment. One of them survives after emergent fasciotomy along with the administration of broad‐spectrum antibiotics and intravenous immunoglobulin.